College of American Pathologists
CAP Committees & Leadership CAP Calendar of Events Estore CAP Media Center CAP Foundation
About CAP    Career Center    Contact Us      
Search: Search
  [Advanced Search]  
CAP Home CAP Advocacy CAP Reference Resources and Publications CAP Education Programs CAP Accreditation and Laboratory Improvement CAP Members
CAP Home > CAP Reference Resources and Publications > CAP TODAY > CAP TODAY 2004 Archive > From transitional cell to urothelial carcinoma
Printable Version

  From transitional cell to
  ruothelial carcinoma


cap today

August 2004
Cover Story

Related article:
Bladder biopsies in step with clinical side

William Check, PhD

A minor but biologically meaningful revision in the new classification for interpreting bladder tumor biopsies is the change from "transitional cell carcinoma" to "urothelial carcinoma." "The big push for that came out of work in the early 50s from grandfather of urologic pathology, Meyer Melicow, MD, at Columbia," says Michael Cohen, MD, head of the Department of Pathology at University of Iowa Health Care. "Dr. Melicow was a representative of that era of urologic pathology in which surgeons were trained in a subspecialty." He was a surgeon designated by his department to be a urologic pathologist. "When he coined the term ’urothelium,’ it met with some resistance among pathologists," Dr. Cohen says. "Their thought was if you had to have urothelium, you might have to have gastrothelium. In hindsight, Dr. Melicow was on the mark." It has become clear that the epithelium that lines the bladder and the rest of the urinary tract is unique. "Urothelium" is now preferred to "transitional cell."

William Check is a medical writer in Wilmette, Ill.




 © 2014 College of American Pathologists. All rights reserved. | Terms and Conditions | CAP ConnectFollow Us on FacebookFollow Us on LinkedInFollow Us on TwitterFollow Us on YouTubeFollow Us on FlickrSubscribe to a CAP RSS Feed